company background image
RUA

Rua BioscienceNZSE:RUA Stock Report

Market Cap

NZ$58.1m

7D

1.2%

1Y

-41.4%

Updated

21 Oct, 2021

Data

Company Financials
RUA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

RUA Overview

Rua Bioscience Limited, a pharmaceutical company, engages in the research, development, cultivation, and manufacturing of cannabinoid derived medicines in New Zealand and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Rua Bioscience
Historical stock prices
Current Share PriceNZ$0.41
52 Week HighNZ$0.37
52 Week LowNZ$0.71
Beta0
1 Month Change6.49%
3 Month Change0%
1 Year Change-41.43%
3 Year Changen/a
5 Year Changen/a
Change since IPO-39.71%

Recent News & Updates

Jul 02
Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation

Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Mar 09
Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation

Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

RUANZ PharmaceuticalsNZ Market
7D1.2%-0.9%0.7%
1Y-41.4%-0.5%2.4%

Return vs Industry: RUA underperformed the NZ Pharmaceuticals industry which returned 1.3% over the past year.

Return vs Market: RUA underperformed the NZ Market which returned 2.8% over the past year.

Price Volatility

Is RUA's price volatile compared to industry and market?
RUA volatility
RUA Beta0
Industry Beta1.29
Market Beta1

Stable Share Price: RUA is more volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: RUA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of NZ stocks.

About the Company

FoundedEmployeesCEOWebsite
201630Rob Mitchellhttps://www.ruabio.com

Rua Bioscience Limited, a pharmaceutical company, engages in the research, development, cultivation, and manufacturing of cannabinoid derived medicines in New Zealand and internationally. The company was formerly known as Hikurangi Cannabis Company Limited and changed its name to Rua Bioscience Limited in October 2019. Rua Bioscience Limited was founded in 2016 and is headquartered in Gisborne, New Zealand.

Rua Bioscience Fundamentals Summary

How do Rua Bioscience's earnings and revenue compare to its market cap?
RUA fundamental statistics
Market CapNZ$58.11m
Earnings (TTM)-NZ$4.42m
Revenue (TTM)n/a

0x

P/S Ratio

-13.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RUA income statement (TTM)
RevenueNZ$0
Cost of RevenueNZ$0
Gross ProfitNZ$0
ExpensesNZ$4.42m
Earnings-NZ$4.42m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.031
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.04%

How did RUA perform over the long term?

See historical performance and comparison

Valuation

Is Rua Bioscience undervalued compared to its fair value and its price relative to the market?

2.02x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RUA is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: RUA is unprofitable, so we can't compare its PE Ratio to the NZ market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RUA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RUA is good value based on its PB Ratio (2x) compared to the XO Pharmaceuticals industry average (3.7x).


Future Growth

How is Rua Bioscience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

60.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rua Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Rua Bioscience performed over the past 5 years?

-57.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: RUA is currently unprofitable.

Growing Profit Margin: RUA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if RUA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare RUA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RUA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: RUA has a negative Return on Equity (-15.32%), as it is currently unprofitable.


Financial Health

How is Rua Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: RUA's short term assets (NZ$17.1M) exceed its short term liabilities (NZ$1.2M).

Long Term Liabilities: RUA's short term assets (NZ$17.1M) exceed its long term liabilities (NZ$842.0K).


Debt to Equity History and Analysis

Debt Level: RUA's debt to equity ratio (0.04%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if RUA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RUA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RUA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 26.3% each year.


Dividend

What is Rua Bioscience current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RUA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RUA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RUA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RUA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RUA's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Rob Mitchell

1.67yrs

Tenure

Mr. Rob Mitchell, PG Dip Bus (Marketing) is the Chief Executive Officer of Rua Bioscience Limited since February 2020. He served as Head of Strategic Marketing - Virology Disease Biology at Roche Palo Alto...


Leadership Team

Experienced Management: RUA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: RUA's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: RUA only recently listed within the past 12 months.


Top Shareholders

Company Information

Rua Bioscience Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Rua Bioscience Limited
  • Ticker: RUA
  • Exchange: NZSE
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NZ$58.113m
  • Shares outstanding: 141.74m
  • Website: https://www.ruabio.com

Number of Employees


Location

  • Rua Bioscience Limited
  • 1 Commerce Place
  • Awapuni
  • Gisborne
  • 4071
  • New Zealand

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:22
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.